Brawn Biotech reported a 26% year-on-year increase in revenue for FY26, reaching ₹169.8 crore. The company’s net loss narrowed significantly to ₹94.1 lakh, down from ₹1.74 crore in the previous fiscal year.

The pharmaceutical distributor scheduled its 41st Annual General Meeting (AGM) for September 29, 2026. Shareholders will vote on the reappointment of director Brij Raj Gupta and the approval of managerial remuneration for Amit Kumar.

Financial Performance

Revenue from operations rose to ₹169.78 crore in FY26 from ₹134.65 crore in FY25. This growth was driven by higher domestic sales and other operating income, which includes commissions and duty drawbacks.

Other income surged nearly fourfold to ₹45.4 lakh, primarily due to rental income rising to ₹36.4 lakh from ₹1.0 lakh in the prior year. Total expenses stood at ₹174.31 crore, closely matching total income.

What the Numbers Show

The narrowing of the net loss was largely non-operational. While the company reported a marginal operating profit before tax of ₹1.1 lakh, the final net loss of ₹94.1 lakh was driven by a ₹93.95 lakh charge for deferred tax assets. This indicates that the improvement in the bottom line is accounting-driven rather than operational.

Balance Sheet & Working Capital

Total assets increased to ₹208.6 crore from ₹204.9 crore. Trade receivables remained stable at ₹54.7 crore, while inventory decreased slightly to ₹100.6 crore. Cash and cash equivalents rose to ₹28.1 lakh from ₹19.9 lakh.

Trade payables saw a significant shift in classification. Current trade payables jumped to ₹144.1 crore from ₹82.4 crore, while non-current payables dropped sharply to ₹12.9 crore from ₹77.1 crore. Total equity increased to ₹43.4 crore, supported by retained earnings adjustments.

Corporate Actions

The AGM agenda includes the reappointment of Brij Raj Gupta, who retires by rotation. Members will also approve the remuneration of ₹9.77 lakh per annum for Manager Amit Kumar for three years. The company has appointed M/s G D S M and Co as its new statutory auditors for a five-year term.

Brawn Biotech reported a net profit of ₹15.44 lakh for the quarter ended June 30, 2026, down from ₹23.60 lakh in the corresponding period of FY25. While total income from operations grew to ₹621.74 lakh from ₹588.86 lakh year-ago, the profitability contraction highlights pressure on operating efficiency.

The board of directors approved the unaudited financial results on August 13, 2026, following recommendations from the Audit Committee. The company also recommended the appointment of M/s G D S M and Co as statutory auditors for a five-year term, subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Financial Performance

Total income from operations increased by 5.6% year-on-year. However, total expenses rose sharply to ₹606.30 lakh from ₹565.26 lakh in Q1FY25, largely due to significant changes in inventory levels.

What the Numbers Show

A divergence between revenue growth and expense inflation is visible in the data. While revenue rose by just over 5%, total expenses climbed by over 7%. This was primarily driven by a surge in "Change in inventories" to ₹295.34 lakh from ₹104.92 lakh in the prior year quarter. This indicates that a significant portion of the cost outflow was tied to inventory accumulation rather than direct consumption or sales, compressing the profit from operations before tax to ₹15.44 lakh from ₹23.60 lakh.

Corporate Actions

Alongside the financial results, the board approved the convening of the 41st Annual General Meeting via Video Conferencing/Other Audio-Visual Means on September 29, 2026. The draft notice for the AGM will be dispatched to shareholders shortly.

The company engaged Rajiv Udai & Associates to conduct the limited review of the interim financial information. The CFO certificate confirmed no material changes in internal controls or instances of fraud during the quarter.